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Objective: The protective effect of adenovirus-mediated ex vivo multigene transfer
with superoxide dismutase, a free radical scavenger, and nitric oxide, a vasodilator
with anti-inflammatory properties, was examined in the rat heart during experimen-
tal ischemia-reperfusion mimicking preservation for cardiac transplantation.
Methods: Donor rat hearts (n 6 per group) were perfused with solution containing
adenoviral vector carrying genes for -galactosidase (group A), endothelial nitric
oxide synthase (group B), manganese superoxide dismutase (group C), or both
endothelial nitric oxide synthase and manganese superoxide dismutase (group D).
Hearts were then implanted heterotopically into the abdomens of recipient rats. Four
days later, transplanted hearts were collected, connected to a Langendorff perfusion
apparatus, and subjected to 6 hours of ischemia followed by 1 hour of reperfusion.
Cardiac function was evaluated with an intraventricular balloon at the beginning of
Langendorff perfusion and after ischemia-reperfusion.
Results: Effective gene transfection was confirmed with X-gal staining in group A
hearts. Positive immunoreactivity for endothelial nitric oxide synthase, manganese
superoxide dismutase, or both was present predominantly in cardiomyocytes in
group B, C, and D hearts. Percentage recovery of preischemic left ventricular
developed pressure was 62.1%  7.36% in group A; recoveries were increased to
79.6%  6.4%, 86.8%  9.1%, and 79.4%  6.2% in groups B, C, and D,
respectively.
Conclusion: These results indicate that adenoviral gene transfer of manganese
superoxide dismutase and endothelial nitric oxide synthase can attenuate myocardial
ischemia-reperfusion injury, with the former providing the most significant protec-
tion. Combined overexpression of manganese superoxide dismutase and endothelial
nitric oxide synthase did not enhance myocardial recovery any further.
Oxidative stress, which is associated with increased formation ofreactive oxygen species, plays a major part in the pathogenesis ofmyocardial ischemia-reperfusion injury.1,2 Superoxide dismutase(SOD) catalyzes the dismutation of superoxide anion to hydrogenperoxide. Three isoforms of SOD exist; copper/zinc SOD, whichhas a cytoplasmic location, extracellular SOD, present outside the
cell, and manganese SOD (Mn-SOD), which is found in the mitochondrial matrix.
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This last isoform can be induced by compounds that in-
crease the production of intracellular superoxide anion.3,4 It
has been demonstrated that Mn-SOD is particularly impor-
tant for myocardial protection because hearts of transgenic
mice overexpressing Mn-SOD demonstrate a remarkable
increase in resistance to ischemia-reperfusion injury.5
Nitric oxide synthase is an enzyme that exists in different
types of cells in several constitutive and inducible isoforms.
The endothelium is a major site for production of nitric
oxide, which is a potent vasodilator6,7 and exerts antineu-
trophil actions that reduce the inflammatory components of
ischemia-reperfusion injury.8 Several studies suggest that
early damage to the coronary endothelium impairs nitric
oxide production.9 It has been shown that nitric oxide may
play an important protective role against cardiac reperfusion
injury after ischemia.10,11 On the other hand, nitric oxide is
reported to react with the superoxide anion to form per-
oxynitrite,12 which exerts deleterious effects leading simul-
taneously to inactivation of nitric oxide,13 such that during
reperfusion neutrophil aggregation and adherence are en-
hanced. These interactions make a strong case for attempt-
ing to overexpress both endothelial nitric oxide synthase
(eNOS) and Mn-SOD together in cardiac cells, which to our
knowledge has not been studied before.
This study was performed in a rat heart model involving
hypothermic coronary perfusion for donor heart gene deliv-
ery, cardioplegic arrest, prolonged hypothermic ischemia,
and reperfusion. We investigated whether multigene adeno-
viral-mediated gene transfer of recombinant genes for Mn-
SOD, eNOS, or both would lead to better myocardial re-
covery after ischemia-reperfusion.
Material and Methods
Animals
Male Sprague-Dawley rats (weight 250-300 g) were used as do-
nors and recipients in this study. All animals received humane care
in compliance with the “Principles of Laboratory Animal Care”
formulated by the National Society for Medical Research, the
Guide for the Care and Use of Laboratory Animals prepared by the
Institute of Laboratory Animal Resources, National Research
Council, and published by the National Academy Press, revised
1996, and the “European Convention on Animal Care” guide. This
study was approved by the institutional ethics committee on ani-
mal research.
Adenoviral Vector
A serotype 5 adenovirus encoding for nonnuclear targeted Esch-
erichia coli -galactosidase under the control of the cytomegalo-
virus promoter was used in the control group (AdCMVLacZ;
provided by James Wilson, Institute for Gene Therapy, University
of Pennsylvania, Philadelphia, Pa). This vector has been rendered
replication defective by replacing the entire E1a region and most
of the E1b region of the adenoviral genome with the complemen-
tary DNA expression cassette. Adenoviral vector carrying the gene
for eNOS was generated as previously described elsewhere.14 In
brief, bovine eNOS complementary DNA was cloned into the
shuttle plasmid pACCMVVpLpA. The resulting plasmid was lin-
earized with Nrul and cotransfected with d1309 into 293 cells by
calcium phosphate-DNA coprecipitation. D1309 is a biologically
selected restriction enzyme site loss variant of wild-type adenovi-
rus type 5, which retains only a single Xba1 site at nucleotide
1339. The 293 cells were human embryonic kidney carcinoma
cells that had been transformed with the left end of human ade-
novirus type 5 DNA. Recombinant adenovirus vectors were gen-
erated by homologous recombination. Viral plaques were picked
and propagated in 293 cells. Viral DNA was enriched by Hirt
extraction and screened by restriction mapping and polymerase
chain reaction for the presence of eNOS complementary DNA.
Positive plaques underwent two further rounds of plaque purifica-
tion in 293 cells. Stocks were prepared from positive plaques, and
these were used to generate high-titer preparations. Viral prepara-
tions were prepared by infecting a confluent monolayer of 293
cells in T175 flasks with viral stock at a multiplicity of infection of
1 to 10. Virus was purified by double cesium gradient ultracen-
trifugation and was dialyzed against 10-mmol/L tris(hydroxymeth-
yl)aminomethane, 1.0-mmol/L magnesium chloride, 1.0-mmol/L
N-2-hydroxyethylpiperazine-N-2-ethanesulfonic acid, and 10%
glycerol for 4 hours at 4°C. Viral titer was determined by plaque
assay. Mn-SOD recombinant adenoviral construct was generated
according to a previously described method. Briefly, Mn-SOD
constructs were generated by cloning of an EcoRI/PvuII fragment
from the pRK5 Mn-SOD construct.15 Recombinant adenoviral
plasmid constructs were generated by cloning transgene into pAd-
.CMVlink, which contains the cytomegalovirus enhancer-pro-
moter and an SV40 polyadenylation site for efficient expression of
the transgene.16 Recombinant virus was generated by cotransfec-
tion of NheI-cut pAd plasmid with ClaI-cut Ad5.sub360 (E3-
deleted) viral DNA.17 After transfection, plates were overlaid with
agar, and initial plaques were harvested for screening by enzymatic
activity. This recombinant virus was screened for Mn-SOD activ-
ity by secondary infection on 293 cells. Initial plaques that ex-
pressed functional enzyme were further purified through two sub-
sequent rounds of plaque purification. Viral titer was determined
by assessing plaque-forming units (pfu) on 293 cells.
Experimental Groups
Rats were divided into four groups according to transfected genes:
group A (control, transfected with AdCMVLacZ) as control, group
B (eNOS, transfected with AdeNOS), group C (Mn-SOD, trans-
fected with AdMnSOD), and group D (both eNOS and Mn-SOD,
transfected with AdeNOS and AdMnSOD). There were 6 rats in
each group. Hearts collected from donor rats were globally trans-
fected by the perfusion method and transplanted into the abdomens
of recipient rats as described in detail. Four days later, a delay
necessary for gene expression, transplanted hearts were excised,
connected to the Langendorff system, and subjected to cold car-
dioplegic arrest and reperfusion accompanied by myocardial func-
tion monitoring and analysis of samples collected at the end by
immunostaining (Figure 1).
Donor Operation and Gene Transfer
Donor rats (250-275 g) were anesthetized with sodium pentobar-
bital (50 mg/kg intraperitoneally). A median laparotomy was per-
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formed to expose the abdominal aorta. After injection of 200 U
aqueous heparin into the inferior vena cava, the aorta was cannu-
lated with a 24-gauge cannula, and the heart was arrested with an
infusion of cold University of Wisconsin solution into the aorta. A
median sternotomy was performed, venae cavae and pulmonary
veins were ligated with 4-0 silk, and the heart was harvested and
stored in the same cardioplegic solution at 4°C.
Gene transfer was achieved through the perfusion method as
described previously elsewhere.18 Briefly, 5 mL of University of
Wisconsin solution containing a viral titer of 1.0  109 pfu/mL in
group A, B, or C. Group D hearts had a total viral dose of 2.0 
109 pfu/mL (1.0  109 pfu/mL of eNOS and 1.0  109 pfu/mL of
Mn-SOD) in 5 mL of University of Wisconsin solution. This
solution was circulated through the coronary vasculature of the
donor heart for 15 minutes by means of a peristaltic pump (Rainin
Instrument, LLC, Oakland, Calif). The viral solution was infused
into the donor organ through the cannula inserted into the aorta and
was collected by a 14-gauge catheter placed into the pulmonary
artery. Both catheters were connected by means of polyvinyl
chloride tubing to the vial containing the viral solution. The flow
rate was 0.75 mL/min. During the perfusion period, the container
with the heart and the vial with the vector were kept on ice, and
temperatures of both solutions did not exceed 4°C.
Heterotopic Heart Transplantation
Heterotopic abdominal heart transplantation was performed with
standard microsurgical techniques.19 In brief, rats (275-300 g)
were anesthetized by intraperitoneal administration of pentobarbi-
tal (70 mg/kg). The donor hearts were transplanted into the recip-
ients by end-to-side anastomoses of the aorta and the pulmonary
artery to the abdominal aorta and inferior vena cava, respectively,
with 8-0 monofilament sutures. During surgery the heart was
wrapped in gauze and kept cold by use of topical ice-cold saline
solution. After the operation, all rats recovered with oxygen in a
warm environment. Viability of the grafts was verified daily by
palpation of the beating transplanted heart.
Global Ischemia-Reperfusion
On the fourth day after gene transfer, animals were anesthetized
with diethyl ether and anticoagulated by intravenous injection of
heparin (500 U). Transplanted hearts were quickly excised and
perfused with modified Krebs-Henseleit buffer (120.0-mmol/L
sodium chloride, 4.5-mmol/L potassium chloride, 20.0-mmol/L
sodium hydrogen carbonate, 1.2-mmol/L potassium phosphate,
1.2-mmol/L magnesium chloride, 2.5-mmol/L calcium chloride,
and 10.0-mmol/L glucose, gassed with 95% carbon dioxide to
obtain pH 7.4 at 37°C) at a pressure equal to 1 cm H2O by means
of a Langendorff apparatus. A thin-walled balloon was inserted
into the left ventricle through the left atrium to monitor left
ventricular pressure and control left ventricular volume. After
stabilization, left ventricular developed pressure (LVDP), mini-
mum dP/dt, maximum dP/dt, and rate-pressure product (RPP, heart
rate  LVDP) were measured with left ventricular diastolic pres-
sure stabilized at 10 mm Hg. The hearts were then subjected to
global ischemia after infusion of cold (4°C) crystalloid (St Thomas
No. 1) cardioplegia for 6 hours followed by 1 hour of reperfusion.
Then the same measurements of the left ventricle were repeated.
X-gal Staining
Group A hearts were dissected, embedded in ornithine carbamoyl-
transferase medium (Miles Inc, Elkhart, Ind), and frozen in liquid
nitrogen. Frozen sections (6 m thick) were fixed in 2% parafor-
maldehyde and 0.125% glutaraldehyde in phosphate-buffered sa-
line solution (PBS) for 5 minutes, washed three times in PBS with
2-mmol/L magnesium chloride, then incubated in three changes of
PBS containing 2-mmol/L magnesium chloride, 0.01% sodium
deoxycholate, and 0.02% NP-40. Sections were then incubated in
staining buffer (30-mmol/L potassium ferrocyanide and 30-
mmol/L potassium ferricyanide in PBS containing 2-mmol/L mag-
nesium chloride, 0.01% sodium deoxycholate, and 0.02% NP-40)
for 2 minutes before incubation in fresh staining buffer containing
1-mg/mL 5-bromo-4-chloro-3-indolyl--D-galactopyranoside (X-
gal) in a moist chamber overnight at 37°C. Subsequently, sections
were rinsed in PBS, counterstained with neutral red, and rinsed in
water before mounting. Blue-stained cells indicated the presence
of -galactosidase expression.
Immunohistochemical Staining
Midventricular cross-sections of the transplanted hearts were em-
bedded in OCT medium and frozen in liquid nitrogen. Frozen
sections (5 m thick) were cut at 25-m intervals, fixed for 10
minutes in cold acetone (4°C), fan dried for 10 minutes, and
further fixed in 1% paraformaldehyde and ethylenediaminetet-
raacetic acid for 3 minutes. Endogenous peroxidase activity was
blocked with 0.1% sodium azide and 0.3% hydrogen peroxide for
10 minutes. Incubation of sections with 5% goat serum in PBS
Figure 1. Experimental protocol. Four days after gene transfection, hearts were subjected to 6 hours of global
ischemia and 1 hour of reperfusion. Hearts were assessed for efficacy of gene transfection with immunohisto-
chemical methods and for function by intraventricular balloon.
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with polysorbate 20 blocked nonspecific protein binding sites.
Samples from groups A, B, and D then had (1:250) anti-eNOS
monoclonal antibody (N30020; Transduction Laboratories, Inc,
Lexington, Ky) added and were incubated for 60 minutes at room
temperature. After rinsing, biotinylated rabbit antimouse F(ab)2
(1:300) was added for 20 minutes. After further incubation for 20
minutes with peroxidase-conjugated streptavidin (1:300), the
slides were incubated for 30 seconds in 0.1-mol/L sodium acetate
buffer, pH 5.2. Then they were placed in 3-amino-9-ethylcarbazole
substrate solution and incubated for 15 minutes at room tempera-
ture, counterstained in mercury-free hematoxylin for 1 minute, and
further rinsed for 3 minutes under cold running tap water before
being mounted. For Mn-SOD staining in groups A, C, and D, a
similar protocol was used, with the primary antibody (K90096C;
BioDesign, New York, NY) at a dilution of 1:200. The secondary
antibody was 1:1000 of sheep/goat peroxidase (M15345).
Statistics
Values are presented as mean SD. One-way analysis of variance
was used, followed by Bonferroni test to indicate individual sig-
nificant differences.
Results
There were no technical failures or operative deaths in the
24 consecutive gene transfection experiments in the study.
Positive cardiomyocyte cytoplasm staining with X-gal can
be seen in cardiomyocytes from the AdCMVLacZ-trans-
fected group but was not observed in nontransfected ani-
mals (Figure 2). Immunohistochemical staining for eNOS in
groups A and B showed weak endothelial expression of
native eNOS in group A and both endothelial and cardio-
myocyte expressions of eNOS in group B (Figure 3). It also
showed a number of inflammatory cells (immunologic re-
action to the adenoviral vector). Figure 4 presents an im-
munohistochemical analysis of Mn-SOD expression in
groups A and C, showing overexpression of Mn-SOD in
myocytes of the group C hearts. Group A hearts showed
weak staining for native Mn-SOD in cardiac myocytes.
Inflammatory cells were found in these slides. Group D
hearts were analyzed separately for eNOS and Mn-SOD;
overexpression of each gene was detected in each sample
tested (Figure 5), with overexpression of eNOS mainly in
endothelial cells and a smaller expression in the cytoplasm
of cardiomyocytes. Overexpression of Mn-SOD was seen in
cardiomyocytes. Some inflammation was also seen in these
samples.
In Langendorff perfusion experiments, no statistically
significant difference was seen before ischemia among the
groups (n  6 in each group; Table 1) in terms of LVDP
(P  .9), minimum dP/dt (P  .274), maximum dP/dt (P 
.106), and RPP (P  .885). Percentage recovery of LVDP
after global ischemia (4°C, 6 hours) is shown in Figure 6.
The percentage recovery of LVDP after ischemia in the
control transfected hearts (group A) reached a peak value of
62.1% 7.3% after reperfusion. In comparison, statistically
significant improvements in the percentage recovery of
LVDP were observed in the group transfected with eNOS
(group B), which reached a peak level of 79.6%  6.4%
(P  .009 vs group A) after reperfusion, and in the group
transfected with eNOS and Mn-SOD (group D), which
reached a level of 79.4%  6.2% (P  .015 vs group A).
The percentage recovery of LVDP was better in Mn-SOD-
transfected hearts (group C), reaching a level of 86.8% 
9.1% (P  .001 vs A). However, the differences between
groups C and B and between groups C and D were not
statistically significant (P  .9 and P  .999, respectively).
Percentage recoveries of minimum and maximum dP/dt
after global ischemia are shown in Figures 7 and 8. Group
B, C, and D hearts showed statistically significantly better
recoveries of minimum and maximum dP/dt than did group
A hearts (P  .001 and P  .001 vs group A, P  .001 and
P  .001 vs group A, and P  .001 and P  .001 vs group
A, respectively). Better recoveries of both minimum and
maximum dP/dt were seen in group C than in groups B and
D, but the differences were not statistically significant (P 
.061 and P  .374, respectively, vs group B and P  .112
and P  .606, respectively, vs group D). Values for mini-
mum and maximum dP/dt were 52.3%  4.4% and 51.3%
 7.2%, respectively, in group A, 72.2%  6.5% and
71.5% 7.2%, respectively, in group B, 81.2% 3.7% and
78.3% 3.3%, respectively, in group C, and 72.8% 4.4%
and 72.3%  4.6%, respectively, in group D.
As shown in Figure 9, group B and C hearts had statis-
tically significantly better percentage recovery of preisch-
emic RPP than did group A and D hearts (78.88%  9.0%
in group B, P  .003 vs group A, and 76.53%  8.1% in
Figure 2. Group A transgene expression. Demonstration of -ga-
lactosidase transgene expression by histochemical staining with
X-gal in heart transfected with AdCMVLacZ. Myocytes stain pos-
itively for -galactosidase (yellow arrows). Original magnifica-
tion 600.
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group C, P  .011 vs group A, compared with 56.5% 
7.1% in group A and 64.6% 7.1% in group D, P .93 vs
group A). Although we did not use pacing on the Langen-
dorff system, heart rate was relatively consistent in the
preischemic period in all four groups studied here. Percent-
age recovery of heart rate after ischemia differed among
groups (group A 70%  4.4%, group B 83.3%  4.3%,
group C 78.4%  6.4%, and group D 71.5%  5.1%).
Group B showed statistically significantly higher percentage
recovery of heart rate after ischemia than did groups A and
D (P  .003 and P  .013, respectively). Differences were
not statistically significant between groups B and C (P 
.602), C and A (P  .187), C and D (P  .559), and D and
A (P  .999).
Discussion
This study demonstrated statistically significant improve-
ment in postischemic recovery of mechanical function in
hearts transfected with genes for eNOS or Mn-SOD relative
to those with control gene transfection in a protocol mim-
Figure 3. Immunohistochemical staining for eNOS. A, Immunohistochemical staining of midventricular section in
heart transfected with AdeNOS with monoclonal antibody to eNOS (counterstained with mercury-free hematoxylin)
showing endothelial (yellow arrows) and cardiomyocyte (red arrows) expressions of eNOS. Some inflammatory
cells can be seen (bright green arrow). Original magnification 400. B, Immunohistochemical staining of
midventricular section of heart transfected with AdCMVLacZ with monoclonal antibody to eNOS (counterstained
with mercury-free hematoxylin) showing some endothelial expression of native eNOS (yellow arrows). Original
magnification 200.
Figure 4. Mn-SOD immunohistochemical staining. A, Immunohistochemical staining of midventricular section of
heart transfected with AdMnSOD with monoclonal antibody to Mn-SOD (counterstained with mercury-free
hematoxylin). Expression is present in cardiomyocytes (red arrows). Original magnification 200. B, Immunohis-
tochemical staining of midventricular section in heart transfected with AdCMVLacZ with monoclonal antibody to
Mn-SOD (counterstained with mercury-free hematoxylin). Some staining of native Mn-SOD can be seen in cardiac
myocytes (red arrows). Original magnification 300.
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icking conditions of preservation for heart transplantation.
However, combined overexpression of both genes did not
lead to further improvement with statistical significance.
These findings appear to provide evidence that overexpres-
sions of both genes play a direct role in the enhancement of
myocardial ischemia-reperfusion tolerance in vivo. How-
ever, combined overexpression of both genes needs further
investigation.
The important role of Mn-SOD in protecting hearts
against the detrimental effects of ischemia-reperfusion in-
jury has been clearly shown by work with transgenic mice
overexpressing Mn-SOD.5 These mice had better postisch-
emic recovery of ventricular function after a period of
ischemia and reperfusion; however, this protocol used a
short period of ischemia, whereas our protocol used a pro-
longed period of hypothermic ischemia after cardioplegic
arrest, which mimics clinical donor heart preservation.
Moreover, in a transgenic animal the heart is genetically
altered to overexpress Mn-SOD; thus it may adapt itself and
acquire a character different from that of the natural heart.
Therefore our model with gene transfection may be more
suitable for investigating the effect of Mn-SOD in poten-
tially useful technique to test the effectiveness of adenoviral
gene transfer. There are three isoforms of SOD: copper/zinc
SOD, which has a cytoplasmic location, extracellular SOD,
found in extracellular compartment, and Mn-SOD, which is
found in the mitochondrial matrix.3 Woo and associates20
found that adenoviral gene transfer of SOD and catalase
attenuates postischemic contractile dysfunction. Recently, it
was shown that in vivo adenoviral gene transfer of extra-
cellular SOD alone provides the heart with substantial pro-
tection against myocardial stunning.21 We have already
shown Mn-SOD to be superior in ameliorating regional
ischemia reperfusion injury.22 In this experiment, we used a
global ischemia-reperfusion injury model, which parallels
clinical heart transplantation.
Figure 5. Immunohistochemical staining for eNOS and Mn-SOD. A, Immunohistochemical staining of midventricular
portion in heart transfected with AdeNOS and AdMnSOD with monoclonal antibody to eNOS (counterstained with
mercury-free hematoxylin). Most eNOS overexpression can be seen in endothelial cells (yellow arrows) with
smaller expression in myocytes (red arrows). Original magnification 200. B, Immunohistochemical staining of
midventricular portion in same heart (transfected with AdeNOS and AdMnSOD) with monoclonal antibody to
Mn-SOD (counterstained with mercury-free hematoxylin). Overexpression of Mn-SOD can be seen in cardiomyo-
cytes (red arrows). Original magnification 200.
TABLE 1. Cardiac function parameters before ischemia during Langendorff perfusion
LVDP
(mm Hg)
Minimum dP/dt
(mm Hg/s)
Maximum dP/dt
(mm Hg/s) RPP
AdCMV LacZ 73.53 19 845.3 92 1156.3 76 15461 7202
eNOS 76.18 22 714.4 123 1060 64 15708 6428
Mn-SOD 82.36 16 780.5 131 1043 72 14740 6305
eNOS and Mn-SOD 77.07 7 860.8 140 1111 71 12686 3871
P value* .901 .274 .106 .885
Data are expressed as mean  SD. There were no significant differences in any of the parameters among the groups before ischemia. n  6 per group.
*Analysis of variance followed by Bonferroni test.
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Our experiment suggests that enhanced enzymatic activ-
ity of eNOS can help to ameliorate the effects of ischemia-
reperfusion in the myocardium. We have demonstrated
overexpression of this gene in the cardiac endothelium and
myocytes. On the other hand, in this study, eNOS was found
to be less effective than Mn-SOD in improving myocardial
recovery after ischemia and reperfusion. The transient na-
ture of the eNOS-derived nitric oxide production is most
Figure 6. Recovery of LVDP after ischemia. Isolated hearts in four
experimental groups (n  6 in each group) were subjected to 6
hours of cold (4°C) global ischemia followed by 1 hour of reper-
fusion. Statistically significantly better recovery of LVDP after
ischemia was shown in groups B, C, and D relative to group A. No
statistically significant differences were found between groups
B, C, or D, although group C hearts showed best recovery. Data
are expressed as percentage of LVDP before ischemia. Asterisk
indicates P  .009 versus group A; double asterisk indicates P <
.001; triple asterisk indicates P  .015. Bar heights represent
mean; error bars represent SD.
Figure 7. Recovery of minimum (min) dP/dt after ischemia (n  6
in each group). Improved recoveries of minimum dP/dt after 6
hours of cold global ischemia and 1 hour of reperfusion were
shown in groups B, C, and D relative to group A. No statistically
significant differences were found between groups B, C, or D,
although group C hearts showed best recovery. Data are ex-
pressed as percentage of basal minimum dP/dt before ischemia.
All asterisks indicate P < .001 versus group A. Bar heights
represent mean; error bars represent SD.
Figure 8. Recovery of maximum (max) dP/dt after ischemia (n  6
in each group). Improved recoveries of maximum dP/dt after 6
hours of cold global ischemia and 1 hour of reperfusion were
shown in groups B, C, and D relative to group A. Differences
between B, C, and D were not statistically significant. Data are
expressed as percentage of baseline maximum dP/dt measured
before ischemia. All asterisks indicate P < .001 versus group A.
Bar heights represent mean; error bars represent SD.
Figure 9. Recovery of RPP after ischemia (n  6 in each group).
Statistically significant improvements in recovery of RPP after 6
hours of cold global ischemia and 1 hour of reperfusion were
shown in groups B and C relative to groups D and A. Difference
between groups D and A was not statistically significant (P 
.93). Data are expressed as percentage of RPP measured before
ischemia. Asterisk indicates P  .003 versus group A and P 
.106 versus group D; double asterisk indicates P  .011 versus
group A and P .307 versus group D. Bar heights represent mean;
error bars represent SD.
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beneficial during the early phase of reperfusion, which may
in part explain our results. In addition to that, nitric oxide
interacts with superoxide anion to form peroxynitrite,12
which in turn exacerbates the deleterious effects of free
radicals and further reduces the ability of nitric oxide to
ameliorate ischemia-reperfusion injury.
Although our results did not demonstrate that combined
overexpressions of eNOS and Mn-SOD provide an additive
protection relative to individual gene transfection, we must
interpret these results with caution. One possible confound-
ing factor is the use of higher virus dose in doubly trans-
fected hearts. Adenovirus as a vector is known to trigger an
inflammatory reaction, which may have been increased in
doubly transfected hearts. Although a number of inflamma-
tory cells were seen on histologic examination of singly and
doubly transfected groups, these hearts did not seem mark-
edly different. Future work is needed with the same vector
carrying both genes together.
Continuous hypothermic perfusion of donor hearts com-
pared with hypothermic immersion storage can be used for
preservation of donor organs.23,24 Therefore a modified hy-
pothermic perfusion technique could be applied for gene
delivery to donor hearts. It was shown that when adenovirus
is used as a vector, this technique would result in more
efficient transgenic expression compared with that induced
by a single bolus injection.18 Pellegrini and colleagues18
showed that adenoviral hypothermic perfusion model pro-
vided an 11- to 14-fold increase in transgenic expression
compared with the high-pressure bolus injection. It allowed
a 30-fold reduction in the viral dose compared with that
found in other reports without affecting the level of trans-
gene expression. Brauner and colleagues25 increased adeno-
viral vector uptake into the donor organ to 80% with the
slow infusion technique (compared with 10% with bolus
injection). Pellegrini and colleagues18 achieved similar lev-
els of gene transfection with lower dose of adenovirus with
no significant inflammatory response. This model of vector
delivery was followed in our experiments. We used positive
staining of myocardial cells as proof of gene transfection.
Inflammatory cells were not specifically stained for. We
showed an application of this model in studying the inter-
action of eNOS and Mn-SOD as important therapeutic
molecules in protecting the myocardium from global isch-
emia-reperfusion injury.
In this study we developed a novel system to study the
cardioprotective roles of different genes in reperfusion in-
jury. It consists of a combination of intracoronary perfusion
of the adenovirus and transplantation to transfer the gene or
genes of interest, followed by Langendorff perfusion to
evaluate the effect on myocardial protection. We believe
that this is a potentially useful technique to test the effec-
tiveness of adenoviral gene transfer and to investigate the
effect of each molecule on myocardial ischemia-reperfusion
injury.
Conclusion
This study demonstrated that gene transfection had potential
to introduce supraphysiologic levels of protective enzymes
such as eNOS and Mn-SOD and to enhance myocardial
tolerance to ischemia beyond that provided by intrinsic
factors. The combined gene transfer of recombinant Mn-
SOD and eNOS in this model had no statistically significant
additive protective effect relative to single gene transfer in
attenuating myocardial damage under conditions of exper-
imental heart transplantation. The value of multigene ther-
apy needs to be investigated further.
We thank John Engelhardt, University of Iowa, for his donation
of the AdMnSOD virus.
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